Sensibilité et résistance aux inhibiteurs des récepteurs Erb B = Sensitivity and resistance to Erb B receptorsDELORD, J.-P; VIGNOT, S; MILANO, G et al.Oncologie (Paris). 2005, Vol 7, Num 8, pp 656-659, issn 1292-3818, 4 p.Article

La biologie des cancers bronchiques et les nouvelles cibles thérapeutiques : état des connaissances et perspectives = Rational and innovative treatments for lung cancer: overview of new approaches and perspectivesDELORD, J.-P; CAUNES, N.Oncologie (Paris). 2002, Vol 4, Num 4, pp 285-291, issn 1292-3818Article

Clinical activity of patupilone in patients with pretreated advanced/ metastatic colon cancer: results of a phase I dose escalation trialMELICHAR, B; CASADO, E; SGUOTTI, C et al.British journal of cancer. 2011, Vol 105, Num 11, pp 1646-1653, issn 0007-0920, 8 p.Article

Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effectPUISSET, F; CHATELUT, E; SPARREBOOM, A et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 2, pp 305-308, issn 0344-5704, 4 p.Article

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patientsVAN CUTSEM, E; VERSLYPE, C; BEALE, P et al.Annals of oncology. 2008, Vol 19, Num 2, pp 332-339, issn 0923-7534, 8 p.Article

Thérapeutiques ciblées et cancers du côlon = Target therapies and colon cancersBUGAT, R; DELORD, J.-P.Oncologie (Paris). 2003, Vol 5, Num 7-8, pp 369-373, issn 1292-3818, 5 p.Article

Toxicité dermatologique des nouvelles thérapies ciblées anticancéreuses utilisées en oncodermatologie = Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatologySIBAUD, V; DELORD, J.-P; CHEVREAU, C et al.Annales de chirurgie plastique et esthétique. 2012, Vol 57, Num 2, pp 106-113, issn 0294-1260, 8 p.Article

Choriocarcinome placentaire métastatique chez la mère et son nouveau né : à propos d'un cas = Metastatic placental choriocarcinoma to mother and newborn : a case reportMAILLY, N; DELORD, J.-P; DUBOIS, A et al.Journal de radiologie (Paris). 2008, Vol 89, Num 4, pp 517-520, issn 0221-0363, 4 p.Article

Spermatic cord sarcoma in adultsMERIMSKY, O; TERRIER, P; BONVALOT, S et al.Acta oncologica (Stockholm). 1999, Vol 38, Num 5, pp 635-638, issn 0284-186XArticle

6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignanciesBRAIN, E. C. G; MITA, A; MISSET, J.-L et al.Journal of cancer research and clinical oncology. 1997, Vol 123, Num 4, pp 227-231, issn 0171-5216Article

Évidement cervical systématique dans les cancers épidermoïdes de la cavité orale = Systematic neck dissection in squamous cell carcinoma of the oral cavityBENLYAZID, A; SARINI, J; MARQUES, B et al.Annales d'oto-laryngologie et de chirurgie cervico-faciale. 2007, Vol 124, Num 6, pp 285-291, issn 0003-438X, 7 p.Article

Population pharmacokinetics of oxaliplatinDELORD, J.-P; UMLIL, A; GUIMBAUD, R et al.Cancer chemotherapy and pharmacology. 2003, Vol 51, Num 2, pp 127-131, issn 0344-5704, 5 p.Article

Le cancer du rein de l'adulte = Adult renal cell carcinomaDELORD, J.-P; ALEXANDRE, J; CHEVREAU, C et al.Bulletin du cancer. 1998, Vol SEP, pp 4-15, issn 0007-4551, SUP1Article

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma modelDELORD, J.-P; QUIDEAU, S; ROCHAIX, P et al.British journal of cancer. 2010, Vol 103, Num 1, pp 61-72, issn 0007-0920, 12 p.Article

A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumorsTHEODORE, C; CHEVREAU, C; YATAQHENE, Y et al.Annals of oncology. 2008, Vol 19, Num 8, pp 1465-1469, issn 0923-7534, 5 p.Article

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiationBALIN-GAUTHIER, D; DELORD, J.-P; PILLAIRE, M.-J et al.British journal of cancer. 2008, Vol 98, Num 1, pp 120-128, issn 0007-0920, 9 p.Article

Lymphome dural primitif. A propos de deux cas et revue de la littérature = Primary dural lymphoma: a report of two cases with review of the literatureBENOUAICH, A; DELORD, J.-P; DANJOU, M et al.Revue neurologique (Paris). 2003, Vol 159, Num 6-7, pp 652-658, issn 0035-3787, 7 p., CAH1Article

Effets secondaires cutanés des nouvelles molécules anticancéreuses : focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l'EGF = Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitorsDESLANDRES, M; SIBAUD, V; CHEVREAU, C et al.Annales de dermatologie et de vénéréologie. 2008, Num JANV, pp 16-24, issn 0151-9638, 9 p., HSArticle

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialLE TOURNEAU, C; PAOLETTI, X; BERNARD, V et al.British journal of cancer. 2014, Vol 111, Num 1, pp 17-24, issn 0007-0920, 8 p.Article

Effets indésirables cutanés des inhibiteurs de BRAF: revue systématique = Adverse skin reactions induced by BRAF inhibitors: A systematic reviewSIBAUD, V; LAMANT, L; MAISONGROSSE, V et al.Annales de dermatologie et de vénéréologie. 2013, Vol 140, Num 8-9, pp 510-520, issn 0151-9638, 11 p.Article

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neckMESIAL, R; RIVERA, F; DELORD, J.-P et al.Annals of oncology. 2010, Vol 21, Num 10, pp 1967-1973, issn 0923-7534, 7 p.Article

Pharmacokinetics of heated intraperitoneal oxaliplatinFERRON, G; DATTEZ, S; GLADIEFF, L et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 4, pp 679-683, issn 0344-5704, 5 p.Article

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patientsROUITS, E; CHARASSON, V; ROBERT, J et al.British journal of cancer. 2008, Vol 99, Num 8, pp 1239-1245, issn 0007-0920, 7 p.Article

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI) : first-line therapy for metastatic colorectal cancerDELORD, J.-P; BENNOUNA, J; NAMAN, H et al.British journal of cancer. 2007, Vol 97, Num 3, pp 297-301, issn 0007-0920, 5 p.Article

Primary sarcomas of the central nervous systemMERIMSKY, O; LEPECHOUX, C; TERRIER, P et al.Oncology. 2000, Vol 58, Num 3, pp 210-214, issn 0030-2414Article